Aytu BioPharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Revenue	57.57	66.38	65.18	73.8	96.67
Revenue Growth	-13.28%	1.84%	-11.68%	-23.66%	47.29%
Cost of Revenue	20.75	20.55	16.13	21.57	46.39
Gross Profit	36.82	45.83	49.05	52.23	50.28
Selling, General & Admin	42.64	38.29	42.04	49.77	69.88
Research & Development	-	1.33	2.77	3.98	12.66
Amortization of Goodwill & Intangibles	2.49	3.68	3.68	3.69	5.84
Operating Expenses	45.13	43.29	48.49	57.44	88.39
Operating Income	-8.32	2.54	0.57	-5.21	-38.1
Interest Expense	-1.9	-3.7	-5.06	-5.15	-0.01
Other Non Operating Income (Expenses)	-4.02	-2.22	-3.13	5.22	0.86
EBT Excluding Unusual Items	-14.23	-3.38	-7.63	-5.14	-37.26
Merger & Restructuring Charges	-	-2.1	-2.16	-	-
Impairment of Goodwill	-	-	-	-	-65.8
Asset Writedown	-	-8.26	-	-2.73	-7.66
Other Unusual Items	-	-	-0.59	0.58	1.82
Pretax Income	-14.23	-13.75	-10.38	-7.29	-108.89
Income Tax Expense	0.02	0.44	2.14	0.26	-0.11
Earnings From Continuing Operations	-14.25	-14.18	-12.52	-7.55	-108.78
Earnings From Discontinued Operations	-	0.62	-3.32	-9.5	-
Net Income	-14.25	-13.56	-15.84	-17.05	-108.78
Net Income to Common	-14.25	-13.56	-15.84	-17.05	-108.78
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	12	6	6	3	1
Shares Outstanding (Diluted)	12	6	6	3	1
Shares Change	96.17%	13.40%	65.81%	127.22%	75.54%
EPS (Basic)	-1.16	-2.16	-2.86	-5.11	-74.01
EPS (Diluted)	-1.16	-2.16	-2.86	-5.11	-74.01
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Free Cash Flow	3.25	-2.17	-1.72	-5.13	-28.82
Free Cash Flow Per Share	0.26	-0.34	-0.31	-1.54	-19.61
Gross Margin	63.95%	69.04%	75.26%	70.77%	52.02%
Operating Margin	-14.44%	3.82%	0.87%	-7.05%	-39.42%
Profit Margin	-24.76%	-20.43%	-24.31%	-23.11%	-112.53%
Free Cash Flow Margin	5.65%	-3.26%	-2.63%	-6.95%	-29.82%
EBITDA	-4.39	7.91	7.29	2.49	-27.96
EBITDA Margin	-7.62%	11.92%	11.18%	3.38%	-28.92%
D&A For EBITDA	3.93	5.38	6.73	7.7	10.15
EBIT	-8.32	2.54	0.57	-5.21	-38.1
EBIT Margin	-14.44%	3.82%	0.87%	-7.05%	-39.42%
Advertising Expenses	-	-	-	-	13.6

SEC Filings: 10-K · 10-Q